PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-03. Numbers and descriptions here follow the published literature rather than marketing material.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Singapore ranked high on the factors of order and security (#3), absence of corruption (#3), regulatory enforcement (#4), civil justice (#8), and criminal justice (#7), and ranked significantly lower on factors of open government (#34), constraints on government powers (#32), and fundamental rights (#38).
In 1964, the first franchise was purchased by former police officer Kermit Bekke. This location, located at 1654 West Carson Street in Torrance, California, had its grand opening on May 28, 1965. Bekke sold his franchise a year and a half later. This location closed in 1975 when it moved across the street to store #1130 at 1619 West Carson Street, which itself would close in the late 1990s and subsequently be repurposed. On January 20, 1967, the 100th Taco Bell grand opening took place in Anaheim, located at 400 South Brookhurst (store #63); this location would later be replaced by a new location at 324 South Brookhurst in 1993. The first Taco Bell restaurant east of the Mississippi River (the 270th to open, store #258) opened at 2050 East Main Street in Springfield, Ohio, on September 20, 1968. Original Taco Bells featured only walk-up window service without indoor seating or drive-thru service. Inside seating was added sporadically in 1968 and drive-thru service was not generally available until 1980. As of 2025, seven original mission-style operating Taco Bell restaurants still remain, located in California and Colorado. A mission-style location (opened in April 1976) that operated in Honolulu, Hawaii (store #1281) remodeled in 2024, and another Mission-style location in Scottsdale, Arizona (store #31, opened circa July 3, 1966) closed on April 12, 2025.
== Ester terminology == IUPAC states normatively that carbamate "esters are often called urethanes or urethans, a usage that is strictly correct only for the ethyl esters." However, as a descriptive matter, the IUPAC recognizes that "An alternative term for the compounds R2NC(=O)OR' (R' not = H), esters of carbamic acids, R2NC(=O)OH, in strict use limited to the ethyl esters, but widely used in the general sense".
== Bulk properties == Radium is the heaviest known alkaline earth metal and is the only radioactive member of its group. Its physical and chemical properties most closely resemble its lighter congener, barium. Pure radium is a volatile, lustrous silvery-white metal, even though its lighter congeners calcium, strontium, and barium have a slight yellow tint. Radium's lustrous surface rapidly becomes black upon exposure to air, likely due to the formation of radium nitride (Ra3N2). Its melting point is either 700 °C (1,292 °F) or 960 °C (1,760 °F) and its boiling point is 1,737 °C (3,159 °F); however, this is not well established. Both of these values are slightly lower than those of barium, confirming periodic trends down the group 2 elements. Like barium and the alkali metals, radium crystallizes in the body-centered cubic structure at standard temperature and pressure: the radium–radium bond distance is 514.8 picometers. Radium has a density of 5.5 g/cm3, higher than that of barium, and the two elements have similar crystal structures (bcc at standard temperature and pressure).
Sources: en.wikipedia.org
Colin Shindler, first professor of Israel Studies in the UK; founding chairman of the European Association of Israeli Studies (EAIS); author of ten books including History Of Modern Israel(Cambridge University Press); main interests lie in evolution of Israeli Right, changes in the approach of the British and European Left towards Israel since 1948 and emigration movement of Soviet Jews between 1917 and 1991; Israel and the European Left: Between Solidarity and Delegitimisation (Continuum/Bloomsbury) was one of first books to examine history of relationship between the British Left and Israel; also wrote Vladimir Jabotinsky, Menahem Begin and Avraham Stern, The Rise of the Israeli Right: From Odesa to Hebron (Cambridge University Press) which was awarded gold medal in The Washington Institute's for Near East Policy's Book Prize competition; writes for the Jewish Chronicle, Jerusalem Post, Haaretz, History Today, Times Literary Supplement; author of over 650 articles and reviews on Israel and Jewish political history. Avi Shlaim, writer, of Iraqi Jewish and Mizrahi Jewish origin; his work focuses on Zionist settlement of the land of Palestine, history of the Nakba and dispossession of Palestinian land. He is one of Israel's New Historians, a group of Israeli scholars who put forward critical interpretations of the history of Zionism and Israel.
== History == Originally, Mohs used a chemical paste (an escharotic agent) to cauterize and kill the tissue. It was made of zinc chloride and bloodroot (the root of the plant Sanguinaria canadensis, which contains the alkaloid sanguinarine). The original ingredients were 40.0 g Stibnite, 10.0 g Sanguinaria canadensis, and 34.5 ml of saturated zinc chloride solution. This paste is similar to black salve or "Hoxsey's paste" (see Hoxsey Therapy), a fraudulent patent medicine, but its usage is different. Hoxsey used the paste for long periods, a harmful practice that was rapidly discredited. Mohs left the paste on the wound only overnight, and the following day, the cancer and surrounding skin would be anesthetized and the cancer removed. The specimen was then excised, and the tissue examined under the microscope. If cancer remained, more paste was applied, and the patient would return the following day. Later, local anesthetic and frozen section histopathology applied to fresh tissue allowed the procedure to be performed the same day, with less tissue destruction, and similar cure rate.
Dehydrogenases oxidize a substrate by transferring hydrogen to an electron acceptor, common electron acceptors being NAD+ or FAD. This would be considered an oxidation of the substrate, in which the substrate either loses hydrogen atoms or gains an oxygen atom (from water). The name "dehydrogenase" is based on the idea that it facilitates the removal (de-) of hydrogen (-hydrogen-) and is an enzyme (-ase). Dehydrogenase reactions come most commonly in two forms: the transfer of a hydride and release of a proton (often with water as a second reactant), and the transfer of two hydrogens.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.